{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:11:05Z","timestamp":1791094265377,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,4,7]],"date-time":"2011-04-07T00:00:00Z","timestamp":1302134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s12032-011-9926-8","type":"journal-article","created":{"date-parts":[[2011,4,7]],"date-time":"2011-04-07T09:21:43Z","timestamp":1302168103000},"page":"1179-1185","source":"Crossref","is-referenced-by-count":35,"title":["Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients"],"prefix":"10.1007","volume":"29","author":[{"given":"Joon Ho","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Nae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon Yang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeoung Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo Kyeoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Hong","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June Won","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,7]]},"reference":[{"key":"9926_CR1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645\u201352.","journal-title":"N Engl J Med"},{"key":"9926_CR2","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928\u201337.","journal-title":"Blood"},{"key":"9926_CR3","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530\u20139.","journal-title":"Blood"},{"key":"9926_CR4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"9926_CR5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"9926_CR6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","volume":"108","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108:1835\u201340.","journal-title":"Blood"},{"key":"9926_CR7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1634\/theoncologist.9-3-259","volume":"9","author":"RM Stone","year":"2004","unstructured":"Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist. 2004;9:259\u201370.","journal-title":"Oncologist"},{"key":"9926_CR8","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.leukres.2008.04.018","volume":"33","author":"T Kiguchi","year":"2009","unstructured":"Kiguchi T, et al. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res. 2009;33:506\u20138.","journal-title":"Leuk Res"},{"key":"9926_CR9","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190\u20136.","journal-title":"Leukemia"},{"key":"9926_CR10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137.","journal-title":"N Engl J Med"},{"key":"9926_CR11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00043426-200306000-00017","volume":"25","author":"C Sandoval","year":"2003","unstructured":"Sandoval C, Giamelli J, Jayabose S. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance. J Pediatr Hematol Oncol. 2003;25:507\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"key":"9926_CR12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487\u201397.","journal-title":"N Engl J Med"},{"key":"9926_CR13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/01.NCC.0000265009.33053.2d","volume":"30","author":"S Moore","year":"2007","unstructured":"Moore S. Facilitating oral chemotherapy treatment and compliance through patient\/family-focused education. Cancer Nurs. 2007;30:112\u201322.","journal-title":"Cancer Nurs"},{"key":"9926_CR14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","volume":"59","author":"K Ruddy","year":"2009","unstructured":"Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56\u201366.","journal-title":"CA Cancer J Clin"},{"key":"9926_CR15","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401\u201311.","journal-title":"Blood"},{"key":"9926_CR16","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038\u201342.","journal-title":"N Engl J Med"},{"key":"9926_CR17","first-page":"6119","volume":"24","author":"J Tsang","year":"2006","unstructured":"Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol (ASCO Ann Meet Proc). 2006;24:6119.","journal-title":"J Clin Oncol (ASCO Ann Meet Proc)"},{"key":"9926_CR18","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, et al. Comparison of imatinib 400\u00a0mg and 800\u00a0mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009;113:4497\u2013504.","journal-title":"Blood"},{"key":"9926_CR19","first-page":"3290","volume":"114","author":"A Bazeos","year":"2009","unstructured":"Bazeos A, et al. Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients. Blood (ASH Ann Meet Abst). 2009;114:3290.","journal-title":"Blood (ASH Ann Meet Abst)"},{"key":"9926_CR20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","volume":"25","author":"T Darkow","year":"2007","unstructured":"Darkow T, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481\u201396.","journal-title":"Pharmacoeconomics"},{"key":"9926_CR21","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1200\/jco.2008.26.15_suppl.6598","volume":"26","author":"P Halpern","year":"2008","unstructured":"Halpern P, et al. Relationship between compliance, costs, hospitalization for CML and GIST patients using imatinib mesylate. J Clin Oncol (ASCO Ann Meet Proc). 2008;26:6598.","journal-title":"J Clin Oncol (ASCO Ann Meet Proc)"},{"key":"9926_CR22","first-page":"6083","volume":"24","author":"HJ Henk","year":"2006","unstructured":"Henk HJ, et al. The impact of non-compliance with imatinib (IM) therapy on health care costs. J Clin Oncol (ASCO Ann Meet Proc). 2006;24:6083.","journal-title":"J Clin Oncol (ASCO Ann Meet Proc)"},{"key":"9926_CR23","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/blood.V110.11.4553.4553","volume":"110","author":"C Doti","year":"2007","unstructured":"Doti C, et al. Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: a case control study. Blood. 2007;110:4553.","journal-title":"Blood"},{"key":"9926_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1758-2652-12-23","volume":"12","author":"R Cohen","year":"2009","unstructured":"Cohen R, et al. Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV\/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc. 2009;12:23.","journal-title":"J Int AIDS Soc"},{"key":"9926_CR25","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.1987.5.9.1469","volume":"5","author":"AM Levine","year":"1987","unstructured":"Levine AM, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol. 1987;5:1469\u201376.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-9926-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-9926-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-9926-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T01:21:30Z","timestamp":1592443290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-9926-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,7]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9926"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-9926-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,7]]}}}